An Overlooked Cardiac Adverse Effect of Letrozol Therapy: Myocardial Infarction due to Coronary Thrombus Formation

S. Yılmaz,S. Avci,U. Canpolat,F. N. Başar
DOI: https://doi.org/10.1111/tbj.12433
2015-07-01
The Breast Journal
Abstract:Letter to Editor: A 48-year-old postmenopausal woman with no previous cardiovascular risk factor was presented to our emergency room with squeezing chest pain and perspiration for 30 minutes. Past medical and family history were unremarkable except breast cancer. She has been diagnosed as infiltrative ductal carcinoma of the left breast and underwent left sided modified radical mastectomy 8 years ago. She also had been given adjuvant chemo/radiotherapy just after surgery. Control visits at oncology department revealed no recurrence for 10 years. During last control visit (15 days ago), positron emission tomography/computed tomography showed recurrence at left axillary lymph nodes. Hence, an aromatase inhibitor (AI) of letrozol 25 mg/ day was initiated. Her chest pain occurred on 5th day of letrozol therapy. Initial electrocardiography on admission revealed acute anterior ST segment elevation myocardial infarction (STEMI) (Fig. 1). Physical examination revealed blood pressure of 120/70 mm Hg, pulse of 77 bpm, normal cardiovascular system findings. Biochemistry panel and hemogram were in normal reference limits. Aspirin 300 mg, unfractioned heparin 4,000 IU bolus, clopidogrel 600 mg, atorvastatin 80 mg, and metoprolol 50 mg were initiated at emergency room. She has been transferred to the cath laboratory for immediate coronary angiography, which showed that normal circumflex and right coronary (RCA) arteries and surplus of intracoronary thrombus formation at proximal segment of left anterior descending artery (LAD) (Fig. 2a). Tirofiban was administered as an intracoronary bolus injection and resulted with no change in thrombus burden (Fig. 2b). Therefore, bare metal stent implantation was performed to the proximal segment of the LAD with excellent angiographic result (Fig. 2c). The patient was followed at the coronary care unit after the procedure. Intravenous tirofiban infusion after percutaneous coronary intervention was continued. The patient discharged from hospital eventless and she was asymptomatic at 3rd month follow-up visits. Recently, as a new class of adjuvant hormonal therapy in hormone-receptor positive breast cancer patients, AIs have gained an important therapeutic
What problem does this paper attempt to address?